Cetuximab News and Research

RSS

Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.

Repurposed quinacrine can reduce tumor burden in mice bearing HNSCC xenograft tumors

The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.

11 Oct 2019

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.

30 Sep 2019

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

A clinical trial has shown that using a combination of three drugs that target a BRAF gene mutation in patients with mCRC effectively boosts overall survival.

30 Sep 2019

Study: Three-drug combination improves overall survival in patients with mCRC

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2019

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Advanced colon cancer often spreads widely and may not respond to standard chemotherapy. In such a case, a novel combination of drugs and flexible dosing may help achieve a better outlook, as demonstrated by several new studies.

8 Jul 2019

Identifying colorectal cancer subtypes in patients could help provide better care

Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.

12 Jun 2019

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

12 Jun 2019

New analysis reveals precision oncology insights for colorectal cancer

Next-generation sequencing of tumor DNA from patients with colorectal cancer revealed genetic alterations that were linked to different survival and treatment outcomes in an analysis led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher.

20 Mar 2019

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Squamous cell carcinoma is one of the most common cancers of the skin and mucosa. Treatment options for the advanced stage have been very limited for patients with tumors of the head and neck, i.e. in the mouth, the pharynx or the larynx: If recurrences or metastases occur during or after platinum-based chemotherapy, the disease is generally considered incurable.

18 Jan 2019

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

New model could predict personalized waiting time for progression in colorectal cancer

An evolutionary model utilizing serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalized waiting time for progression.

30 Aug 2018

'Plastic antibodies' effectively target and eliminate tumor cells

A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells.

23 Aug 2018

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Patients with a greater than 10 pack/year history of smoking tend to develop an especially dangerous form of head and neck squamous cell cancer for which prognosis remains poor and treatments have changed little during the past two decades.

14 Aug 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Researchers develop new methods for studying evolution of cancer treatment resistance

New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center.

3 Jul 2018

Colorado researchers suggest new combination therapy for advanced head and neck cancer

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab.

7 Jun 2018

Researchers explore targeted second-line treatment for colorectal cancer

Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction.

5 Jun 2018

Highly sensitive ELISA method for analysis of CET in plasma samples

This article explores the development, full optimization and validation study of a highly sensitive and selective ELISA for determination of cetuximab (CET) in human plasma samples.

23 Feb 2018

Cetuximab News and Research

Further Reading

Repurposed quinacrine can reduce tumor burden in mice bearing HNSCC xenograft tumors

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

Study: Three-drug combination improves overall survival in patients with mCRC

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

New analysis reveals precision oncology insights for colorectal cancer

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Toxic effects of drugs in the lungs 'more widespread than thought'

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

New model could predict personalized waiting time for progression in colorectal cancer

'Plastic antibodies' effectively target and eliminate tumor cells

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Researchers develop new methods for studying evolution of cancer treatment resistance

Colorado researchers suggest new combination therapy for advanced head and neck cancer

Researchers explore targeted second-line treatment for colorectal cancer

Highly sensitive ELISA method for analysis of CET in plasma samples

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News